LUPIN.NSライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (8 5月 2024 @ 18:59):

Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs)...

Stats
本日の出来高	1.69M
平均出来高	1.17M
時価総額	736.56B
EPS	INR7.86 ( 2024-05-07 )
次の収益日	( INR12.29 ) 2024-08-01
Last Dividend	INR4.00 ( 2023-07-14 )
Next Dividend	INR0 ( N/A )
P/E	38.59
ATR14	INR1.820 (0.11%)

ボリューム相関

長: -0.62 (weak negative)

短: -0.75 (moderate negative)

Signal:(48.456) Neutral

Lupin Limited 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Lupin Limited 相関 - 通貨/商品

-0.15
( neutral )

-0.26
( neutral )

-0.21
( neutral )

-0.53
( weak negative )

0.09
( neutral )

0.55
( weak )

Lupin Limited 財務諸表

Annual	2022
収益:	INR162.70B
総利益:	INR94.90B (58.33 %)
EPS:	INR9.46

FY	2022
収益:	INR162.70B
総利益:	INR94.90B (58.33 %)
EPS:	INR9.46

FY	2022
収益:	INR161.93B
総利益:	INR91.05B (56.23 %)
EPS:	INR-33.24

FY	2021
収益:	INR149.29B
総利益:	INR95.67B (64.08 %)
EPS:	INR26.84

Financial Reports:

No articles found.

Lupin Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR4.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR4.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Lupin Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.31 - low (43.35%) | Divividend Growth Potential Score: 3.91 - Decrease likely (21.81%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.250	2002-01-24
Last Dividend	INR4.00	2023-07-14
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	24	--
Total Paid Out	INR80.35	--
Avg. Dividend % Per Year	0.37%	--
Score	2.12	--
Div. Sustainability Score	4.31
Div.Growth Potential Score	3.91
Div. Directional Score	4.11	--

Next Divdend (Est)
(2024-06-03)

INR3.85 Estimate 3.18 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.12

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR5.00	0.65%
2019	INR5.00	0.59%
2020	INR6.00	0.78%
2021	INR6.50	0.65%
2022	INR4.00	0.42%
2023	INR4.00	0.55%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SANGHVIMOV.NS	Dividend Junior	2023-08-04	Sporadic	18	0.41%
M&MFIN.NS	Dividend Junior	2023-07-20	Annually	19	1.20%
GLOBUSSPR.NS	Dividend Junior	2023-07-14	Sporadic	15	0.36%
ASTEC.NS	Dividend Junior	2023-07-20	Annually	15	0.08%
TIPSINDLTD.NS	Dividend Knight	2023-08-03	Annually	17	0.03%
PEL.NS	Dividend Junior	2023-06-16	Annually	29	1.59%
JAICORPLTD.NS	Dividend Junior	2023-09-04	Annually	17	0.27%
DBCORP.NS	Dividend Knight	2023-08-01	Semi-Annually	15	3.47%
SIGIND.NS	Ex Dividend Junior	2023-09-22	Annually	11	0.62%
MAZDA.NS	Dividend Junior	2023-09-07	Annually	8	1.43%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0938	1.500	8.12	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.139	1.500	9.57	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	7.49	1.000	8.34	8.34	[3 - 30]
operatingCashFlowPerShareTTM	33.77	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	33.77	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.643	1.000	2.62	2.62	[0.2 - 0.8]
operatingProfitMarginTTM	0.131	1.000	9.39	9.39	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.31

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	41.11	1.000	5.95	0	[1 - 100]
returnOnEquityTTM	0.139	2.50	9.72	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	33.77	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.247	1.500	3.82	0	[0 - 0.4]
operatingCashFlowPerShareTTM	33.77	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.291	1.500	-1.392	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0806	1.000	-0.486	0	[0.1 - 0.5]
Total Score				3.91

Lupin Limited

Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women's health, and anti-tuberculosis. The company is also involved in the provision of biosimilar and over-the-counter products; specialty products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities. Lupin Limited network consists of 18 labs, 280 LupiMitra collection centers, and 450 pick-up points. It operates in India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.